Response to EGFR inhibitors: Are more mutations better?
from Medscape Genomic Medicine
Investigators in China examined tumor samples from 100 patients with lung cancer to determine whether the quantity of epidermal growth factor receptor mutations within a lung cancer influences the clinical activity of an EGFR tyrosine kinase inhibitor. All patients had received gefitinib at some point during the course of their disease, either as part of a clinical trial or in clinical practice; the tissue samples retrieved from the tissue bank had been obtained at diagnosis.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063